CLINICAL TRIALS NEWS
Biopharma firm Appili Therapeutics has announced the dosing of the first participant in its Phase III trial analysing oral Avigan tablets (favipiravir) for treating Covid-19 in the US.
Developed by FUJIFILM Toyama Chemical, Avigan is a broad-spectrum antiviral oral tablet.
PRA Health Sciences has been engaged as the clinical research organisation (CRO) to carry out the trial at 47 outpatient sites, Appili noted.
The Phase III Preventing Severe COVID Disease (PRESECO) study will evaluate the efficacy of Avigan for treating patients with confirmed Covid-19 and mild-to-moderate symptoms.
It plans to alleviate symptoms and prevent disease progression before the infection requires hospitalisations or intensive interventions.
The randomised, double-blind, placebo-controlled study will have around 826 participants.
This is the second Appili-sponsored Covid-19 trial that has started dosing in the current quarter of the year.
Early data from the PRESECO study is expected in the first half of next year.
Comments
Post a Comment